Get 40% Off
🤯 This Tech Portfolio is up 29% YTD! Join Now to Get April’s Top PicksGet The Picks – Just 99 USD

Genocea Biosciences Stock Dives After Early Data From GEN-011 Trial In Pretreated Solid Tumor Patients

Published 08/04/2022, 19:32
Updated 08/04/2022, 20:10
© Reuters.  Genocea Biosciences Stock Dives After Early Data From GEN-011 Trial In Pretreated Solid Tumor Patients

© Reuters. Genocea Biosciences Stock Dives After Early Data From GEN-011 Trial In Pretreated Solid Tumor Patients

Genocea Biosciences Inc (NASDAQ: GNCA) has shared initial data from Phase 1/2a TiTAN trial OF GEN-011 in patients with refractory solid tumors.

  • The company says that the early results presented at American Association for Cancer Research (AACR) show anti-tumor activity despite the lower intensity regimens and heavily pretreated tumors.
  • Stable disease was seen at the initial Day 57 scan in four of the five patients. While all patients had progressive disease (PD) at their Day 113 scan, three of the five experienced clear biologic changes after infusion.
  • A patient with metastatic non-small cell lung cancer (NSCLC) experienced a 10% reduction in tumor diameters (approx. 30% reduction in volume) and resolution of tumor-associated cough.
  • None of the initial patients have experienced dose-limiting toxicities, with no self-reactivity or autoimmune toxicity evidence.
  • Overall, the range of Grade 2 and Grade 3 treatment-emergent adverse events (TEAEs) align with expected toxicity from cell therapy regimens.
  • Additional data presented at AACR highlights ongoing work characterizing inhibitory antigens or Inhibigens.
  • A preclinical poster presented at the meeting demonstrates how detrimental these Inhibigens are to the efficacy of cancer therapeutics in mouse models of melanoma and pancreatic cancer.
  • Price Action: GNCA shares are down 51.5% at $0.63 during the market session on the last check Friday.
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Read at Benzinga

Read the original article on Benzinga

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.